Shunnan Zhang
Research Subjects
Shunnan Zhang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Cunhao Li
College of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
1 shared publicationFenglian Zhang
Tasly Pharmaceut Grp Co Ltd, State Key Lab Core Technol Innovat Chinese Med, Tianjin 300410, Peoples R China
1 shared publicationHaibin Qu
Tasly Holding Group
1 shared publicationHaiou Dong
Tasly Holding Group
1 shared publicationJiahao Feng
College of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
1 shared publicationJianlu Qu
College of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
1 shared publication
Latest Publications
- 8 July 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26 (6) , 1-13
Optimization and Evaluation of Colchicine Patch Formulation Based on Box-Behnken Design
This study aimed to optimize colchicine (COL) transdermal patches to enhance key quality attributes, including adhesion, drug release, and transdermal pene
- 8 July 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26 (6) , 1-13
Optimization and Evaluation of Colchicine Patch Formulation Based on Box-Behnken Design
This study aimed to optimize colchicine (COL) transdermal patches to enhance key quality attributes, including adhesion, drug release, and transdermal pene
- 1 April 2022
- Vol. 77 (3-4) , 125-130
Traditional use and safety evaluation of combination Traditional Chinese Medicine in European registration: with XiaoYao Tablets as an example
Mental health disorders such as stress, anxiety, depression and insomnia caused by COVID-19 have attracted worldwide attention. Traditional Chinese medicines (TCMs) have been proven to be a safe and effective option for treating mental health disorders. Recently, after assessing its efficacy and safety fully, the Netherlands Medicines Evaluation Board approved XiaoYao Tablets as a traditional herbal medicinal product (THMP), indicated for an alternative self-care for patients in Europe to relieve the symptoms of mental stress and exhaustion. Despite the fact that TCMs have gradually become one of the therapeutic choices worldwide, to-date, only a few TCMs have been successfully registered in the European Union (EU) as THMPs, and XiaoYao Tablets is the first successfully registered combination TCM from China. In this article, traditional use efficacy and clinical safety of XiaoYao Tablets in the treatment of mental health disorders were summarized and analyzed from the perspective of traditional use registration (TUR). Additionally a safety evolution pathway of combination TCMs was established. This article will not only seek to enhance our understanding about traditional use efficacy and clinical safety of XiaoYao Tablets, but also summarize the experience of XiaoYao Tablets as the first successfully registered combination TCM from China, which could serve as role model for the others to overcome registration difficulties in the EU.
- 1 April 2022
- Vol. 77 (3-4) , 125-130
Traditional use and safety evaluation of combination Traditional Chinese Medicine in European registration: with XiaoYao Tablets as an example
Mental health disorders such as stress, anxiety, depression and insomnia caused by COVID-19 have attracted worldwide attention. Traditional Chinese medicines (TCMs) have been proven to be a safe and effective option for treating mental health disorders. Recently, after assessing its efficacy and safety fully, the Netherlands Medicines Evaluation Board approved XiaoYao Tablets as a traditional herbal medicinal product (THMP), indicated for an alternative self-care for patients in Europe to relieve the symptoms of mental stress and exhaustion. Despite the fact that TCMs have gradually become one of the therapeutic choices worldwide, to-date, only a few TCMs have been successfully registered in the European Union (EU) as THMPs, and XiaoYao Tablets is the first successfully registered combination TCM from China. In this article, traditional use efficacy and clinical safety of XiaoYao Tablets in the treatment of mental health disorders were summarized and analyzed from the perspective of traditional use registration (TUR). Additionally a safety evolution pathway of combination TCMs was established. This article will not only seek to enhance our understanding about traditional use efficacy and clinical safety of XiaoYao Tablets, but also summarize the experience of XiaoYao Tablets as the first successfully registered combination TCM from China, which could serve as role model for the others to overcome registration difficulties in the EU.
- 28 October 2014
- Published by Springer Nature
- p. 459-509
Quality Control of Dantonic™